CDTX

Cidara Therapeutics Inc

Add to Watchlist

Advanced Chart

21.540

+0.060(+0.280%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

22.060

Open

21.370

VWAP

21.52

Vol

50.81K

Mkt Cap

235.94M

Low

20.950

Amount

1.09M

EV/EBITDA(TTM)

Total Shares

4.56M

46.69M

EV/OCF(TTM)

P/S(TTM)

107.21

Cidara Therapeutics, Inc. is a biotechnology company. The Company is focused on the discovery, development and commercialization of therapeutics designed for patients facing serious diseases. The Company's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. The Company’s primary focus is using its Cloudbreak platform to develop a potential new class of drugs called drug-Fc conjugates (DFCs), for the prevention and treatment of serious diseases. This technology couples’ potent inhibitors to a human antibody fragment to create long-acting DFCs designed to inhibit multiple disease targets. Its advanced DFC program is CD388, a long-acting antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2024Q4

FY2025Q1

240.00K

-98.64%

0.00

-100%

Estimates Revision

The market is revising No Change the revenue expectations for Cidara Therapeutics, Inc. (CDTX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 13.85%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+13.85%

In Past 3 Month

5 Analyst Rating

74.09% Upside

Wall Street analysts forecast CDTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDTX is 37.50 USD with a low forecast of 34.00 USD and a high forecast of 46.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

74.09% Upside

Current: 21.540

Low

34.00

Averages

37.50

High

46.00

74.09% Upside

Current: 21.540

Low

34.00

Averages

37.50

High

46.00

Needham

Joseph Stringer

Strong Buy

Reiterates

$35

2025-04-10

Reason

Needham

Joseph Stringer

Price Target

$35

2025-04-10

Reiterates

Strong Buy

Reason

Citizens Capital Markets

Roy Buchanan

Buy

Initiates

$46

2025-03-12

Reason

Citizens Capital Markets

Roy Buchanan

Price Target

$46

2025-03-12

Initiates

Buy

Reason

Citizens JMP analyst Roy Buchanan initiated coverage of Cidara Therapeutics with an Outperform rating and $46 price target. Potential Phase 2b results for influenza prevention expected in Q2 could point to a billion-dollar opportunity, while supporting the broader viability of Cidara's novel platform technology, the analyst tells investors in a research note. The firm says the company is developing a hybrid small-molecule technology called drug-Fc conjugates, which have a distinct therapeutic mechanism, in effect ultra-long, half-life small molecules.

HC Wainwright & Co.

Ed Arce

Strong Buy

Maintains

$24 → $35

2025-03-10

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$24 → $35

2025-03-10

Maintains

Strong Buy

Reason

Needham

Joseph Stringer

Strong Buy

Reiterates

$35

2025-03-07

Reason

Needham

Joseph Stringer

Price Target

$35

2025-03-07

Reiterates

Strong Buy

Reason

RBC Capital

Gregory Renza

Buy

Initiates

$34

2024-12-13

Reason

RBC Capital

Gregory Renza

Price Target

$34

2024-12-13

Initiates

Buy

Reason

RBC Capital analyst Gregory Renza initiated coverage of Cidara Therapeutics with an Outperform rating and $34 price target. The firm sees the commercial potential for CD388, an innovative therapeutic class based on Cidara's Cloudbreak platform. The unique mechanism of action of CD388 could provide universal protection against broad influenza viruses and throughout the flu season, the analyst tells investors in a research note. RBC believes "there is currently room" for new flu prevention innovations, and its projections estimate that CD388 could achieve global peak revenues of $1.1B by 2033.

WBB Securities

Stephen Brozak

Strong Buy

Maintains

$40 → $45

2024-12-05

Reason

WBB Securities

Stephen Brozak

Price Target

$40 → $45

2024-12-05

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Cidara Therapeutics Inc (CDTX.O) is -2.09, compared to its 5-year average forward P/E of -2.84. For a more detailed relative valuation and DCF analysis to assess Cidara Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.84

Current PE

-2.09

Overvalued PE

2.50

Undervalued PE

-8.18

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.07

Current EV/EBITDA

0.26

Overvalued EV/EBITDA

0.77

Undervalued EV/EBITDA

-0.91

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

60.32

Current PS

0.00

Overvalued PS

268.74

Undervalued PS

-148.10

Financials

Annual

Quarterly

FY2024Q4

YoY :

-100.00%

0.00

Total Revenue

FY2024Q4

YoY :

+522.71%

-54.18M

Operating Profit

FY2024Q4

YoY :

+540.13%

-52.37M

Net Income after Tax

FY2024Q4

YoY :

+654.93%

-5.36

EPS - Diluted

FY2024Q4

YoY :

+128.02%

-29.41M

Free Cash Flow

FY2024Q4

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2024Q4

YoY :

+13965.41%

-13.86K

FCF Margin - %

FY2024Q4

YoY :

+4399.45%

-13.36K

Net Margin - %

FY2024Q4

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 253.84% over the last month.

Sold

0-3

Months

75.5K

USD

3-6

Months

0.0

USD

6-9

Months

21.3K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

105.7K

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 129.45% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

2.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

3.2M

Volume

Months

6-9

1.4M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areSelling! The selling amount has increased 253.84% over the last month.

Sold

0-3

Months

75.5K

USD

3-6

Months

0.0

USD

6-9

Months

21.3K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

105.7K

USD

Months

CDTX News & Events

Events Timeline

2025-03-24 (ET)

2025-03-24

07:14:49

Elicio Therapeutics appoints Preetam Shah as chief strategy, financial officer

2025-03-18 (ET)

2025-03-18

08:05:53

Cidara Therapeutics to present on CD388 at ICAR 2025

2025-03-17 (ET)

2025-03-17

06:16:02

Cidara Therapeutics: CD388 preclinical data published in Nature Microbiology

News

5.0

04-16Globenewswire

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

1.0

03-19Newsfilter

Cidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza Preparedness and Response

9.0

03-18Newsfilter

Cidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025

People Also Watch

Ambac Financial Group Inc

Thornburg Income Builder Opportunities Trust

KULR Technology Group Inc

FAQ

What is Cidara Therapeutics Inc (CDTX) stock price today?

The current price of CDTX is 21.54 USD — it has increased 0.28 % in the last trading day.

CDTX

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

CDTX News & Events

Events Timeline

News

People Also Watch

FAQ

What is Cidara Therapeutics Inc (CDTX) stock price today?

What is Cidara Therapeutics Inc (CDTX)'s business?

What is the price predicton of CDTX Stock?

What is Cidara Therapeutics Inc (CDTX)'s revenue for the last quarter?

What is Cidara Therapeutics Inc (CDTX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Cidara Therapeutics Inc (CDTX)'s fundamentals?

How many employees does Cidara Therapeutics Inc (CDTX). have?

What is Cidara Therapeutics Inc (CDTX) market cap?